Stéphanie Blanquet-Diot obtained an MSc degree in Nutrition and Food Science in 1999 and a PhD degree in Biotechnology, Nutrition and Health from Université d’Auvergne in 2002.

She became associate professor at Université Clermont Auvergne (UCA) in 2004 and currently is deputy Director of the UCA/INRAE 454 MEDIS (Microbiology, Digestive Environment and Health) research group.

She is also scientific manager of the in vitro gut simulation platform DIGEST’iv that combines oral, gastric, intestinal and colonic models. She has strong expertise in digestive physiology, nutrition, microbiology and in vitro modelling of the human and monogastric animal digestive environment under physiological and diseased situations (obesity and inflammatory bowel syndrome). She is particularly interested in enteric pathogens, pro/prebiotics, vegetal extracts and drugs interactions with intestinal microbiota.

She co-authored around 90 publications and book chapters.


UMR 454 MEDIS Microbiology Digestive Environment and Health
Université Clermont Auvergne


France 🇫🇷 


In vitro gut models as a powerful platform for microbiome research in animal nutrition and health

Numerous studies have shown the key roles of digestion and gut microbiota in animal nutrition and health. For technical, cost and regulatory reasons (European 3Rs rules), in vitro gut models are increasingly used as a relevant alternative to in vivo assays to evaluate the fate of feed or pharma compounds in the digestive tract.

A large range of in vitro systems have been developed the last two decades, ranging from static mono-compartmental models to dynamic multicompartmental ones.

This talk introduces the main dynamic in vitro models currently available for animal researches considering the physicochemical, mechanical and/or microbial parameters of animal digestion, focusing on pigs and dogs. Then, the potential of those systems will be given in the fields of animal nutrition and health, particularly by studying bilateral interactions of gut microbiome with nutrients, probiotics, enteric pathogens or drugs. The limitation and challenge facing in vitro gut models will be lastly discussed, such as coupling with cellular models for improved host-microbe interactions studies or adaptation to pathological conditions, such as obesity.